Myopathy with statin-fibrate combination therapy: Clinical considerations

Nature Reviews Endocrinology

Volumn 5, Issue 9, 2009, Pages 507-518

  Jacobson, Terry A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE 1A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MIBEFRADIL; PRAVASTATIN; REPAGLINIDE; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TRILIPIX; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; AREA UNDER THE CURVE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TRANSPORT; DRUG WITHDRAWAL; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GLUCURONIDATION; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; INSULIN RESISTANCE; MUSCLE CRAMP; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; MYALGIA; MYOPATHY; MYOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTILIPEMIC AGENTS; CLOFIBRIC ACID; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PROCETOFEN;

EID: 70349334010     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2009.151     Document Type: Review

References (122)

1. Bloomfield, H. E. The role of fibrates in a statin world. Arch. Intern. Med. 166, 715-716 (2006).
2. Abbott. TriCor® (fenofibrate tablets) Us full prescribing information [online], http://www.rxabbott.com/pdf/tricorpi.pdf (2008).
3. Abbott. Trilipix® (fenofibric acid) delayed release capsules Us full prescribing information [online] http://www.rxabbott.com/pdf/trilipix-pi.pdf (2008).
4. Pfizer. Lopid® (gemfibrozil tablets) Us full prescribing information [online], http://media.Pfizer.com/files/products/uspi-lopid.pdf (2008).
5. Nakamura, Y. Pharmacogenomics and drug toxicity. N. Engl. J. Med. 359, 856-858 (2008).
6. Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
7. Frick, M. H. et al. Helsinki Heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317, 1237-1245 (1987).
8. [authors listed] WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal investigators Lancet 2 379-385 1980.
9. Thompson, P. D., Clarkson, P. & Karas, R. H. Statin-associated myopathy. JAMA 289, 1681-1690 (2003).
10. Omar, M. A. & wilson, J. P. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36, 288-295 (2002).
11. Graham, D. J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (2004).
12. Pasternak, R. C. et al. ACC/AHA/NHLBi Clinical advisory on the use and safety of statins. Circulation 106, 1024-1028 (2002).
13. McKenney, J. M., Davidson, M. H., Jacobson, T. A., Guyton, J. R. & National Lipid Association statin safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association statin safety Assessment Task Force. Am. J. Cardiol. 97 (Suppl. 1), s89-s94 (2006).
14. Phillips, P. S. et al. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 137, 581-585 (2002).
15. Shek, A. & Ferrill, M. J. Statin-fibrate combination therapy. Ann. Pharmacother. 35, 908-917 (2001).
16. Law, M. & rudnicka, A. R. Statin safety: a systematic review. Am. J. Cardiol. 97 (Suppl. 1), s52-s60 (2006).
17. Shanahan, R. L., Kerzee, J. A., Sandhoff, B. G., Carroll, N. M. & Merenich, J. A. Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization. Pharmacotherapy 25, 345-351 (2005).
18. Toth, P. P. , Harper, C. R. & Jacobson, T. A. Clinical characterization and molecular mechanisms of statin myopathy. Expert. Rev. Cardiovasc. Ther. 6, 955-969 (2008).
19. Laaksonen, R. On the mechanisms of statin-induced myopathy. Clin. Pharmacol. Ther. 79, 529-531 (2006).
20. Chapman, M. J. & Carrie, A. Mechanisms of statin-induced myopathy: a role for the ubiquitin-proteasome pathway Arterioscler. Thromb. Vasc. Biol. 25, 2441-2444 (2005).
21. Noël, B. Regarding the mechanism of statin-induced myopathy. Am. Heart J. 149, e3 (2005).
22. Vladutiu, G. D. et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34, 153-162 (2006).
23. Oh, J., Ban, M. R., Miskie, B. A., Pollex, R. L. & Hegele, R. A. Genetic determinants of statin intolerance. Lipids Health Dis. 6, 7 (2007).
24. Diaczok, B. J. & shali, R. Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. South Med. J. 96, 318-320 (2003).
25. Brewer, H. B. J R. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 92 (Suppl. 2), 23-29 (2003).
26. Chucrallah, A., De Girolami, U., Freeman, R. & Federman, M. Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study. Eur. Neurol. 32, 293-296 (1992).
27. Stange, E. F. et al. Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment. Atherosclerosis 91, 257-265 (1991).
28. Schneider, A., Stange, E. F. , Ditschuneit, H. H. & Ditschuneit, H. Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients. Atherosclerosis 56, 257-262 (1985).
29. Farswan, M., Rathod, S. P. , Upaganlawar, A. B. & semwal, A. Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. Indian J. Exp. Biol. 43, 845-848 (2005).
30. Owczarek, J., Jasinska, M. & Orszulak-Michalak, D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol. Rep. 57, 23-34 (2005).
31. Dirks, A. J. & Jones, K. M. Statin-induced apoptosis and skeletal myopathy. Am. J. Physiol. Cell Physiol. 291, C1208-C1212 (2006).
32. Sacher, J., Weigl, L., Werner, M., Szegedi, C. & Hohenegger, M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J. Pharmacol. Exp. Ther. 314, 1032-1041 (2005).
33. Flint, O. P. , Masters, B. A., Gregg, R. E. & Durham, S. K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol. Appl. Pharmacol. 145, 91-98 (1997).
34. Laaksonen, R. et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am. J. Cardiol. 77, 851-854 (1996).
35. Maeda, T., Kawane, T. & Horiuchi, N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144, 681-692 (2003).
36. Collisson, E. A. et al. Atorvastatin prevents rhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol. Cancer Ther. 2, 941-948 (2003).
37. Maeda, T. & Horiuchi, N. Simvastatin suppresses leptin expression in 3T3-L1 adipocytes via activation of the cyclic AMP-PKA pathway induced by inhibition of protein prenylation. J. Biochem. 145, 771-781 (2009).
38. Jantzen, F. et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J. Physiol. Pharmacol. 58, 503-514 (2007).
39. Blanco-Colio, L. M. et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and rho A prenylation. Atherosclerosis 161, 17-26 (2002).
40. Mutoh, T. , Kumano, T. , Nakagawa, H. & Kuriyama, M. Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts. FEBS Lett. 444, 85-89 (1999).
41. Li, X. et al. Inhibition of protein geranylgeranylation and rhoA/rhoA kinase pathway induces apoptosis in human endothelial cells. J. Biol. Chem. 277, 15309-15316 (2002).
42. Nagashima, T. , Okazaki, H., Yudoh, K., Matsuno, H. & Minota, S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: a potential therapeutic approach to rheumatoid arthritis. Arthritis Rheum. 54, 579-586 (2006).
43. Zhong, W. B., Wang, C. Y. , Chang, T. C. & Lee, W. S. Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis. Endocrinology 144, 3852-3859 (2003).
44. Ikemoto, T. & endo, M. Properties of Ca2+ release induced by clofibric acid from the sarcoplasmic reticulum of mouse skeletal muscle fibres. Br. J. Pharmacol. 134, 719-728 (2001). (Pubitemid 33016142)
45. Rao, R. V. et al. Coupling endoplasmic reticulum stress to the cell death program. Mechanism of caspase activation. J. Biol. Chem. 276, 33869-33874 (2001).
46. Zhou, S. & wallace, K. B. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol. Sci. 48, 82-89 (1999).
47. Akiyama, M. et al. Novel duplication mutation in the patatin domain of adipose triglyceride lipase (PNPLA2) in neutral lipid storage disease with severe myopathy. Muscle Nerve 36, 856-859 (2007).
48. Campagna, F. et al. Novel mutations in the adipose triglyceride lipase gene causing neutral lipid storage disease with myopathy. Biochem. Biophys. Res. Commun. 377, 843-846 (2008).
49. Fischer, J. et al. The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat. Genet. 39, 28-30 (2007). (Pubitemid 46026498)
50. Molokhia, M., Bhatia, S. & Nitsch, D. Genetic determinants of statin-associated myopathy. Per. Med. 5, 481-494 (2008).
51. Hagenbuch, B. & Meier, P. J. Organic anion transporting polypeptides of the OATP/sLC21 family: phylogenetic classification as OATP/sLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447, 653-665 (2004).
52. Mano, Y. , Usui, T. & Kamimura, H. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab. Dispos. 35, 2040-2044 (2007). (Pubitemid 350005193)
53. Goosen, T. C. et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab. Dispos. 35, 1315-1324 (2007).
54. Prueksaritanont, T. et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm. Res. 22, 71-78 (2005).
55. Prueksaritanont, T. et al. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm. Res. 22, 1101-1109 (2005).
56. Prueksaritanont, T. et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 301, 1042-1051 (2002).
57. Prueksaritanont, T. et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30, 1280-1287 (2002).
58. Wen, X., Wang, J. S., Backman, J. T. , Kivistö, K. T. & Neuvonen, P. J. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 29, 1359-1361 (2001).
59. Prueksaritanont, T. et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30, 505-512 (2002).
60. Shitara, Y. , Hirano, M., Sato, H. & sugiyama, Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP/OATP1B1; sLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interactions between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004).
61. Niemi, M., Backman, J. T. , Juntti-Patinen, L., Neuvonen, M. & Neuvonen, P. J. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br. J. Clin. Pharmacol. 60, 208-217 (2005).
62. Wang, J. S., Neuvonen, M., Wen, X., Backman, J. T. & Neuvonen, P. J. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 30, 1352-1356 (2002).
63. VHA Pharmacy Benefits Management-strategic Healthcare Group and The Medical Advisory Panel Statin-Fibrate Report: Focus on Safety [online], http://www.pbm.va.gov/safety%20reports/87ry38statin-fibrate-final.pdf (2004).
64. SeArCH Collaborative Group. et al. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N. Engl. J. Med. 359, 789-799 (2008).
65. Noé, J., Portmann, R., Brun, M. E. & Funk, C. Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 35, 1308-1314 (2007).
66. Yamazaki, M. et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2-and P-glycoprotein-mediated transport. Xenobiotica 35, 737-753 (2005).
67. Hirano, M., Maeda, K., Shitara, Y. & sugiyama, Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab. Dispos. 34, 1229-1236 (2006).
68. Ho, R. H. et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
69. Kopplow, K., Letschert, K., König, J., Walter, B. & Keppler, D. Human hepatobiliary transport of organic anions analyzed by quadruple- transfected cells. Mol. Pharmacol. 68, 1031-1038 (2005).
70. Nezasa, K., Higaki, K., Takeuchi, M., Nakano, M. & Koike, M. Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin. Xenobiotica 33, 379-388 (2003).
71. Hsiang, B. et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168 (1999).
72. Kalliokoski, A., Backman, J. T. , Kurkinen, K. J., Neuvonen, P. J. & Niemi, M. Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin. Pharmacol. Ther. 84, 488-496 (2008).
73. Boyd, R. A. et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol. 40, 91-98 (2000).
74. Schneck, D. W. et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75, 455-463 (2004).
75. Nakagomi-Hagihara, R., Nakai, D. & Tokui, T. Inhibition of human organic anion transporter 3-mediated pravastatin transport by gemfibrozil and its metabolites in humans. Xenobiotica 37, 416-426 (2007).
76. Nakagomi-Hagihara, R., Nakai, D., Tokui, T. , Abe, T. & ikeda, T. Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica 37, 474-486 (2007).
77. Jacobson, T. A. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert Opin. Drug Saf. 2, 269-286 (2003).
78. Gustavson, L. E. et al. The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3α-hydroxy isomeric metabolite. J. Clin. Pharmacol. 45, 947-953 (2005).
79. Pan, W. J. et al. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J. Clin. Pharmacol. 40, 316-323 (2000).
80. Martin, P. D., Dane, A. L., Schneck, D. W. & warwick, M. J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin. Ther. 25, 459-471 (2003).
81. Zhu, T. et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J. Clin. Pharmacol. 49, 63-71 (2008).
82. Kyrklund, C., Backman, J. T., Neuvonen, M. & Neuvonen, P. J. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73, 538-544 (2003). (Pubitemid 37249124)
83. Kyrklund, C. et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69, 340-345 (2001).
84. Spence, J. D., Munoz, C. E., Hendricks, L., Latchinian, L. & Khouri, H. E. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am. J. Cardiol. 76, 80A-83A (1995).
85. Durrington, P. N., Tuomilehto, J., Hamann, A., Kallend, D. & smith, K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res. Clin. Pract. 64, 137-151 (2004).
86. Farnier, M. et al. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am. Heart J. 153, 335e1-335e8 (2007).
87. Gil-extremera, B. et al. Efficacy and safety of ezetimibe/simvastatin co-administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 5, 305-314 (2007). (Pubitemid 350208898)
88. Grundy, S. M. et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the sAFAri trial). Am. J. Cardiol. 95, 462-468 (2005).
89. Koh, K. K. et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J. Am. Coll. Cardiol. 45, 1649-1653 (2005).
90. Derosa, G. et al. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin. Ther. 26, 1599-1607 (2004).
91. Vega, G. L. et al. Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am. J. Cardiol. 91, 956-960 (2003).
92. Farnier, M. & Dejager, S. Effect of combined fluvastatin-fenofibrate therapy compared with fenofibrate monotherapy in severe primary hypercholesterolemia. French Fluvastatin study Group. Am. J. Cardiol. 85, 53-57 (2000).
93. Kayikçiolu, M., Ozerkan, F. & soydan, I. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia. Am. J. Cardiol. 83, 1135-1137 (1999).
94. Ellen, R. L. & McPherson, R. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia. Am. J. Cardiol. 81, 60B-65B (1998).
95. Wierzbicki, A. S., Lumb, P. J., Cheung, J. & Crook, M. A. Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. QJM 90, 631-634 (1997).
96. Wägner, A. M., Jorba, O., Bonet, R., Ordóñez-Llanos, J. & Pérez, A. Efficacy of atorvastatin and gemfibrozil, alone and in low dose combination, in the treatment of diabetic dyslipidemia. J. Clin. Endocrinol. Metab. 88, 3212-3217 (2003).
97. Vergoulas, G. et al. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil. Transpl. Int. 13 (Suppl. 1), s64-s67 (2000).
98. Murdock, D. K. et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am. Heart J. 138, 151-155 (1999).
99. Iliadis, E. A. & rosenson, R. S. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia. Clin. Cardiol. 22, 25-28 (1999).
100. Smit, J. W. et al. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am. J. Cardiol. 76, 126A-128A (1995).
101. Rosenson, R. S. & Frauenheim, W. A. Safety of combined pravastatin-gemfibrozil therapy. Am. J. Cardiol. 74, 499-500 (1994).
102. Wiklund, O. et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am. J. Med. 94, 13-20 (1993).
103. Peters, J. R., Kubo, S. H., Olivari, M. T. , Knutson, K. R. & Hunninghake, D. B. Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil ± lovastatin. Am. J. Cardiol. 71, 1485-1488 (1993).
104. Feussner, G., Eichinger, M. & Ziegler, R. The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type iii hyperlipoproteinemia. Clin. Investig. 70, 1027-1035 (1992).
105. Glueck, C. J., Speirs, J. & Tracy, T. Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias. J. Lab. Clin. Med. 115, 603-609 (1990).
106. Illingworth, D. R. & Bacon, S. Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia. Circulation 79, 590-596 (1989). (Pubitemid 19087710)
107. Jones, P. H. et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 204, 208-215 (2009).
108. Davidson, M. H., Clark, J. A., Glass, L. M. & Kanumalla, A. Statin safety: an appraisal from the adverse event reporting system. Am. J. Cardiol. 97, 32C-43C (2006).
109. Weber. J. C. P. In Side Effects of Antiinflammatory/Analgesic Drugs: Advances in Inflammation Research 6th edn (eds rainsford, K. D. & Velo, G. P. ) 1-7 (raven, New York, 1984).
110. Jones, P. H. & Davidson, M. H. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am. J. Cardiol. 95, 120-122 (2005).
111. Holoshitz, N., Alsheikh-Ali, A. A. & Karas, R. H. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am. J. Cardiol. 101, 95-97 (2008).
112. Chang, J. T. , staffa, J. A., Parks, M. & Green, L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol. Drug Saf. 13, 417-426 (2004).
113. Wandel, C., Kim, R. B., Guengerich, F. P. & wood, A. J. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro. Drug Metab. Dispos. 28, 895-898 (2000).
114. Shitara, Y. , itoh, T. , sato, H., Li, A. P. & sugiyama, Y. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J. Pharmacol. Exp. Ther. 304, 610-616 (2003).
115. Kajosaari, L. I. et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 78, 388-399 (2005).
116. Ejendal, K. F. & Hrycyna, C. A. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol. Pharmacol. 67, 902-911 (2005).
117. Smith, S. C. Jr. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update, endorsed by the National Heart, Lung, and Blood institute. Circulation 113, 2363-2372 (2006)
118. Harper, C. R. & Jacobson, T. A. Managing dyslipidemia in chronic kidney disease. J. Am. Coll. Cardiol. 51, 2375-2384 (2008).
119. Bruckert, E., Hayem, G., Dejager, S., Yau, C. & Bégaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients- the PriMO study. Cardiovasc. Drugs Ther. 19, 403-414 (2005).
120. Rubins, H. B. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol intervention Trial study Group. N. Engl. J. Med. 341, 410-418 (1999).
121. Robins, S. J. et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans Affairs HDL intervention Trial (vA-HiT). Diabetes Care 26, 1513-1517 (2003).
122. Ginsberg, H. N. et al. Evolution of the lipid trial protocol of the Action to Control Cardiovascular risk in Diabetes (ACCOrD) trial. Am. J. Cardiol. 99 (Part A), 56i-67i (2007).